What Is Lung Cancer Screening?
Lung cancer screening is a systematic approach to detecting lung cancer at an early stage — before symptoms develop — using an annual low-dose computed tomography (LDCT) scan of the chest. It targets people at elevated risk because of their smoking history, because the earlier lung cancer is found, the greater the chance of successful treatment.
Lung cancer is the leading cause of cancer death globally and in Australia. Most cases are diagnosed at an advanced stage — when the cancer has already spread — because early-stage disease causes no symptoms. Five-year survival for late-stage lung cancer is in the range of 5–15%. Survival for stage I disease treated with surgery can approach 70–90%. The gap between early and late detection is the rationale for screening.
Key Points
- Low-dose CT (LDCT) is the only lung cancer screening modality with demonstrated reduction in lung cancer mortality in randomised trials.
- USPSTF (2021) recommends annual LDCT for adults aged 50–80 with a 20 or more pack-year smoking history who currently smoke or have quit within the past 15 years.
- A pack-year equals smoking one pack (20 cigarettes) per day for one year — cumulative exposure is what matters for eligibility.
- Former smokers who quit up to 15 years ago remain eligible because lung cancer risk takes years to decline after quitting.
- The National Lung Screening Trial (NLST) showed annual LDCT reduced lung cancer mortality by 20% compared with chest X-ray.
- The NELSON trial showed approximately 24% reduction in lung cancer mortality in men and 33% in women compared with no screening.
- Harms include false positives, unnecessary invasive procedures, radiation exposure, overdiagnosis, and incidental findings.
- Most positive screens are false positives — the large majority of detected nodules are benign.
- Australia has no national lung cancer screening program as of 2026.
- Shared decision-making with a clinician is the appropriate framework — not a blanket recommendation for all smokers.
What LDCT Screening Involves
LDCT uses a CT scanner with substantially reduced radiation compared with a standard diagnostic chest CT.
- Duration: approximately 5–10 minutes; the actual scan acquisition is under 30 seconds
- Position: lying on your back on the scanner table, arms raised above the head
- Breathing: you will be asked to hold your breath briefly (approximately 5–6 seconds) during image acquisition
- No injection, contrast, or preparation required
- Radiation dose: approximately 1–3 millisieverts (mSv) per scan — roughly equivalent to six months of natural background radiation. A standard diagnostic chest CT delivers approximately 5–7 mSv; a chest X-ray approximately 0.1 mSv.
Images are reviewed by a radiologist who reports on the presence, size, and characteristics of any lung nodules. Findings are categorised using the Lung-RADS system (Lung CT Screening Reporting and Data System), which guides whether the next step is routine annual screening, short-interval follow-up CT, or further investigation.
Eligibility Criteria
Current International Guideline Criteria
| Organisation | Age | Smoking History | Former Smokers |
|---|---|---|---|
| USPSTF (2021) | 50–80 years | ≥20 pack-years | Quit within past 15 years |
| American Cancer Society (2023) | 45–75 years | ≥20 pack-years | Quit within past 15 years |
| NHS (UK) Targeted Lung Health Checks | 55–74 years | Significant ever-smoker or ex-smoker | Varies by programme |
These criteria aim to identify people at sufficient risk that the benefits of screening outweigh the harms. Screening people at lower risk — light or never-smokers — increases the harm-to-benefit ratio: more false positives and procedures for less cancer detected.
Understanding Pack-Years
A pack-year is a standardised measure of cumulative tobacco exposure.
Calculation: packs smoked per day × years smoked = pack-years
| Smoking Pattern | Years Smoked | Pack-Years |
|---|---|---|
| 1 pack per day | 20 years | 20 pack-years |
| 2 packs per day | 15 years | 30 pack-years |
| ½ pack per day | 40 years | 20 pack-years |
| ¼ pack per day | 80 years | 20 pack-years |
| 1 pack per day | 30 years | 30 pack-years |
Pack-years capture that a light smoker over many decades and a heavy smoker over fewer years can have similar cumulative risk. The threshold matters more than daily amount alone.
Current Smokers
Current smokers who meet age and pack-year criteria benefit from screening. Stopping smoking substantially reduces future lung cancer risk and the risk of other conditions the scan may reveal incidentally. Clinicians discussing lung cancer screening with current smokers should also offer or refer for smoking cessation support.
Former Smokers
Former smokers who quit within the past 15 years and meet age and pack-year criteria remain eligible because lung cancer risk does not immediately normalise after quitting. Risk declines progressively over years, but former heavy smokers remain at elevated absolute risk for an extended period.
Who Is Not Eligible
- Never-smokers (absent other specific high-risk features such as strong occupational exposure history)
- People outside the recommended age range with no other high-risk features
- People whose smoking history falls below the pack-year threshold
- People with serious comorbidities or limited life expectancy, where early detection would not translate into meaningful benefit
Evidence for Screening
National Lung Screening Trial (NLST)
The NLST, conducted in the United States, enrolled over 53,000 adults aged 55–74 with a 30 or more pack-year smoking history who smoked currently or had quit within 15 years. Participants were randomised to annual LDCT or annual chest X-ray for three rounds.
Result: Annual LDCT reduced lung cancer mortality by 20% compared with chest X-ray, and all-cause mortality by 6.7%.
NELSON Trial (Europe)
The NELSON trial, conducted across the Netherlands and Belgium, enrolled men and women aged 50–74 with significant smoking histories, randomised to volume-based LDCT screening versus no screening.
Results at 10-year follow-up:
- Men: 24% reduction in lung cancer mortality
- Women: 33% reduction in lung cancer mortality
The larger reduction seen in women may reflect differences in the biology of screen-detected lung cancers or differences in participation and follow-up patterns.
Clinical Significance
Both major randomised trials demonstrate that annual LDCT — in the right population — reduces the chance of dying from lung cancer. This is the basis for the shift from observational interest to active clinical recommendation across multiple jurisdictions.
Benefits
- Mortality reduction: Two large randomised trials demonstrate significant reduction in lung cancer deaths among eligible participants.
- Stage shift: Screening shifts detection toward earlier-stage disease, when curative resection is possible and survival is substantially higher.
- Survival advantage: Stage I non-small cell lung cancer, surgically resected, has a five-year survival of approximately 70–90%. Stage IV disease: approximately 5–15%.
- Opportunity for cessation: The screening encounter is associated with increased uptake of smoking cessation programmes in some studies.
Risks and Harms
False Positives
False positives are the most common harm of lung cancer screening. In the NLST, approximately 25% of LDCT scans yielded a positive result (a nodule or abnormality requiring follow-up). Of those positive results, the large majority were not cancer — fewer than 4% of positive screens represented confirmed lung cancer.
False positives cause:
- Anxiety and psychological distress
- Additional imaging (repeat LDCT at a shorter interval)
- Occasionally, invasive procedures (bronchoscopy, needle biopsy) with their own procedural risks
Most false positives are resolved with a repeat scan showing a stable or disappearing nodule — no invasive procedure required.
Overdiagnosis
Lung cancer screening detects some cancers that would never have become symptomatic in the person’s lifetime. These include very slow-growing adenocarcinomas — particularly ground-glass nodules and lepidic-predominant tumours — and cancers in people who will die of another cause before the cancer progresses.
Estimates of overdiagnosis in lung cancer screening trials range from approximately 9–18% of screen-detected cancers. This is lower than overdiagnosis estimates for some other cancers, because many detected lung cancers, even early-stage ones, are biologically significant. Treatment of an overdiagnosed lung cancer — typically surgery — exposes patients to risks without benefit.
Radiation Exposure
Each annual LDCT scan delivers approximately 1–3 mSv of radiation. Cumulative exposure over a screening programme spanning many years is not trivial, though the absolute increase in radiation-induced cancer risk is estimated to be small relative to the mortality benefit of detecting lung cancer in eligible high-risk individuals. The USPSTF has assessed the radiation risk as acceptable within the recommended eligibility criteria.
Incidental Findings
LDCT images the entire chest and may detect abnormalities unrelated to the screening indication:
- Coronary artery calcification
- Emphysema or features of COPD
- Pleural disease
- Aortic abnormalities
- Thyroid nodules (at the base of the neck)
- Adrenal or liver lesions on lower-slice protocols
Incidental findings may trigger further investigations, additional imaging, and anxiety for conditions that may or may not be clinically important. Managing incidental findings appropriately is an important part of any screening programme.
Lung Nodule Management: Lung-RADS
The Lung-RADS system (American College of Radiology) classifies screening findings from 0 to 4, guiding recommended follow-up:
| Lung-RADS Category | Description | Probability of Malignancy | Recommended Action |
|---|---|---|---|
| 0 | Incomplete — prior images needed | — | Repeat scan or retrieve prior imaging |
| 1 | No nodules, or definitely benign findings | <1% | Routine annual screening |
| 2 | Probably benign; small solid or ground-glass nodules | <1% | Routine annual screening |
| 3 | Probably benign; needs short-term follow-up | 1–2% | 6-month LDCT |
| 4A | Suspicious; intermediate risk | 5–15% | 3-month LDCT or PET/CT |
| 4B | Very suspicious; high risk | ≥15% | Tissue sampling or PET/CT |
| 4X | Category 3 or 4 with additional concerning features | — | Specialist referral |
A Lung-RADS 3 or higher result does not mean cancer — it means a lower-risk nodule needs closer watching, or a higher-risk nodule warrants further evaluation. Most people with an elevated Lung-RADS result will ultimately have benign findings confirmed.
Shared Decision-Making
Lung cancer screening is not a standard test to be ordered routinely for all eligible smokers without a proper conversation. Shared decision-making is essential because:
- The benefits are real but require annual commitment over many years
- The harms — particularly false positives — are common
- Individual values regarding follow-up procedures and the possibility of incidental findings vary
- A single screen has limited value; benefit comes from sustained annual participation
A useful conversation with your clinician covers:
- Do you meet eligibility criteria? Age, pack-year history, and smoking status.
- What does a positive scan mean? Most positive scans are not cancer; most require repeat imaging, not biopsy.
- What happens if cancer is found? Early-stage cancer is usually treated with surgery or radiotherapy; outcomes are substantially better than late-stage disease.
- Are you willing to continue annually? Benefit accrues over a sustained programme.
- What is your overall health? Screening is less beneficial if life expectancy is significantly limited by other conditions.
- Are you prepared for follow-up anxiety? Receiving a positive result — even one that turns out to be benign — causes real distress in many people.
Smoking Cessation and Screening
For current smokers meeting screening criteria, cessation remains the most important single step for reducing lung cancer risk — and for reducing overall mortality. Screening does not replace cessation.
Importantly, screening and cessation should be delivered together:
- The screening encounter creates a natural opportunity for a cessation conversation
- Some evidence suggests that participation in a screening programme can increase motivation to quit
- Quitting also reduces cardiovascular disease, COPD, and many other conditions
See: Smoking Cessation — Methods, Support, and What Actually Works
Australian Context
As of June 2026, Australia has no national organised lung cancer screening program. LDCT lung cancer screening does not attract a Medicare rebate for screening purposes.
Australian Pilot Programs
The Australian government funded a national lung cancer screening pilot that enrolled high-risk current and former smokers and demonstrated feasibility, participant uptake, and a lung cancer detection rate consistent with international trial results. Recommendations for a national program implementation were made based on pilot data. Policy and funding decisions were under government consideration as of 2026.
Guideline Positions
- Cancer Council Australia: Supports lung cancer screening for high-risk populations on the basis of international trial evidence; advocates for a nationally funded program.
- Cancer Australia: Acknowledges the evidence base and supports ongoing evaluation and implementation planning.
- RACGP: Recognises the evidence for LDCT in eligible high-risk individuals; recommends an informed individual discussion for patients who meet criteria, noting that access and Medicare funding remain limited.
Practical Access
Without a national program, Australians meeting eligibility criteria may:
- Discuss private LDCT with their GP (available at many radiology providers, though out-of-pocket costs apply)
- Enquire about access through public hospital lung health or thoracic oncology clinics
- Ask about enrolment in research studies or trials where available
A GP referral is required for LDCT in most Australian contexts.
Further Reading
- USPSTF — Lung Cancer Screening (2021) — US Preventive Services Task Force recommendation statement
- Cancer Council Australia — Lung Cancer — Australian patient information on lung cancer
- Cancer Australia — Lung Cancer — Australian government cancer authority position and resources
- RACGP — Guidelines for Preventive Activities in General Practice — Red Book guidance on cancer screening
- NCI — Lung Cancer Screening (PDQ) — US National Cancer Institute patient information
- American Cancer Society — Lung Cancer Screening — ACS eligibility recommendations
- Lung Foundation Australia — Australian lung health patient support and advocacy
Related Guides
- Preventive Screening Hub
- Cancer — Guide Hub
- Smoking Cessation — Methods, Support, and What Actually Works
- COPD: Chronic Obstructive Pulmonary Disease
- Respiratory Hub
- PSA Screening: Benefits, Risks, and Shared Decision-Making
Last updated: June 2026
This guide is for educational purposes only and is not a substitute for professional medical advice. Lung cancer screening eligibility criteria and Medicare funding may change as policy is updated. Speak with your GP about whether low-dose CT screening is appropriate for you.